Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash from Investing Activities: 2010-2025

Historic Cash from Investing Activities for Heron Therapeutics (HRTX) over the last 11 years, with Sep 2025 value amounting to $11.9 million.

  • Heron Therapeutics' Cash from Investing Activities rose 198.69% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.9 million, marking a year-over-year increase of 2235.26%. This contributed to the annual value of $18.7 million for FY2024, which is 4.00% up from last year.
  • Heron Therapeutics' Cash from Investing Activities amounted to $11.9 million in Q3 2025, which was up 61.69% from $7.3 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Cash from Investing Activities ranged from a high of $39.7 million in Q2 2021 and a low of -$36.0 million during Q3 2022.
  • Moreover, its 3-year median value for Cash from Investing Activities was $4.0 million (2024), whereas its average is $5.3 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first spiked by 351.98% in 2022, then slumped by 537.21% in 2023.
  • Over the past 5 years, Heron Therapeutics' Cash from Investing Activities (Quarterly) stood at -$24.3 million in 2021, then soared by 108.33% to $2.0 million in 2022, then plummeted by 537.21% to -$8.8 million in 2023, then soared by 229.22% to $11.4 million in 2024, then soared by 198.69% to $11.9 million in 2025.
  • Its Cash from Investing Activities was $11.9 million in Q3 2025, compared to $7.3 million in Q2 2025 and $2.3 million in Q1 2025.